Literature DB >> 12428249

Determinants and sequelae associated with utilization of acetaminophen versus traditional nonsteroidal antiinflammatory drugs in an elderly population.

Elham Rahme1, Dan Pettitt, Jacques LeLorier.   

Abstract

OBJECTIVE: Acetaminophen is recommended as initial therapy for patients with arthritis, particularly those at increased risk of nonsteroidal antiinflammatory drug (NSAID)-induced gastrointestinal (GI) side effects. However, higher doses of acetaminophen inhibit prostaglandin synthesis and have been associated with GI events. This study was undertaken to compare the observed and adjusted rates of GI events (hospitalizations, ulcers, dyspepsia, GI prophylaxis) occurring with higher versus lower doses of acetaminophen.
METHODS: This was a retrospective cohort study of subjects ages >or=65 years who received a prescription for acetaminophen or NSAID between 1994 and 1996. Pharmaceutical and medical records were reviewed for 1 year of historical data prior to the index prescription of acetaminophen or non-aspirin NSAID. Risk factors for GI events were identified based on the historical data. To further control for bias, patients were categorized by propensity score (the likelihood of receiving acetaminophen, given defined risk factor values). Records were then reviewed for the duration of the index prescription or 30 days, whichever was less, to generate data on the occurrence of GI events. Determinants of acetaminophen utilization were identified using logistic regression, and rates of GI events for each therapy were examined using Poisson regression analyses, controlling for duration of exposure, individual risk factors, and propensity scores.
RESULTS: The study included 26,978 patients in the NSAID cohort and 21,207 in the acetaminophen cohort. Determinants of acetaminophen utilization compared with NSAIDs (odds ratio [95% confidence interval]) included recent hospitalization (8.6 [7.7-9.5]), concomitant anticoagulation therapy (3.2 [2.7-3.8]), age >85 years (2.3 [2.1-2.4]), and history of prior GI events, especially those requiring hospitalization (14.6 [11.7-18.7]). Unadjusted rates of GI hospitalization, ulcer, and dyspepsia were higher for patients in the acetaminophen cohort than for those in the NSAID cohort. The occurrence of GI events in acetaminophen-treated patients was dose dependent, with rate ratios (compared with high-dose NSAIDs and adjusted for risk susceptibility) ranging from 0.6 (95% confidence interval 0.5-0.7) for <or=650 mg/day to 1.0 (0.9-1.1) for >3,250 mg/day.
CONCLUSION: In this cohort, acetaminophen utilization is more common in patients at higher risk of GI events. After adjustment for risk susceptibility, patients receiving higher doses of acetaminophen have higher rates of GI events compared with those receiving lower doses.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12428249     DOI: 10.1002/art.10604

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  19 in total

Review 1.  EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).

Authors:  W Zhang; M Doherty; N Arden; B Bannwarth; J Bijlsma; K-P Gunther; H J Hauselmann; G Herrero-Beaumont; K Jordan; P Kaklamanis; B Leeb; M Lequesne; S Lohmander; B Mazieres; E Martin-Mola; K Pavelka; A Pendleton; L Punzi; B Swoboda; R Varatojo; G Verbruggen; I Zimmermann-Gorska; M Dougados
Journal:  Ann Rheum Dis       Date:  2004-10-07       Impact factor: 19.103

Review 2.  A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods.

Authors:  Til Stürmer; Manisha Joshi; Robert J Glynn; Jerry Avorn; Kenneth J Rothman; Sebastian Schneeweiss
Journal:  J Clin Epidemiol       Date:  2005-10-13       Impact factor: 6.437

3.  Green-lipped mussel (Perna canaliculus) extract efficacy in knee osteoarthritis and improvement in gastrointestinal dysfunction: a pilot study.

Authors:  Samantha Coulson; Phillip Vecchio; Helen Gramotnev; Luis Vitetta
Journal:  Inflammopharmacology       Date:  2012-02-26       Impact factor: 4.473

Review 4.  Management issues with elderly-onset rheumatoid arthritis: an update.

Authors:  Ignazio Olivieri; Carlo Palazzi; Giovanni Peruz; Angela Padula
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

Review 5.  Paracetamol (acetaminophen): a blessing or a hidden curse?

Authors:  M W Whitehouse; D E Butters
Journal:  Inflammopharmacology       Date:  2013-09-27       Impact factor: 4.473

6.  Patient Preference for Placebo, Acetaminophen (paracetamol) or Celecoxib Efficacy Studies (PACES): two randomised, double blind, placebo controlled, crossover clinical trials in patients with knee or hip osteoarthritis.

Authors:  T Pincus; G Koch; H Lei; B Mangal; T Sokka; R Moskowitz; F Wolfe; A Gibofsky; L Simon; S Zlotnick; J G Fort
Journal:  Ann Rheum Dis       Date:  2004-04-13       Impact factor: 19.103

Review 7.  Chronic neck pain: how to approach treatment.

Authors:  David G Borenstein
Journal:  Curr Pain Headache Rep       Date:  2007-12

8.  Patterns of antibiotic use and risk of hospital admission because of Clostridium difficile infection.

Authors:  Sandra Dial; Abbas Kezouh; Andre Dascal; Alan Barkun; Samy Suissa
Journal:  CMAJ       Date:  2008-10-07       Impact factor: 8.262

Review 9.  Does paracetamol (acetaminophen) reduce the pain of osteoarthritis? A meta-analysis of randomised controlled trials.

Authors:  W Zhang; A Jones; M Doherty
Journal:  Ann Rheum Dis       Date:  2004-03-05       Impact factor: 19.103

10.  Adherence to weekly oral bisphosphonate therapy: cost of wasted drugs and fractures.

Authors:  O Sheehy; C Kindundu; M Barbeau; J LeLorier
Journal:  Osteoporos Int       Date:  2009-01-20       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.